1. South Korea Stocks

  2. •

    Distribution services

  3. •

    Medical distributors
Hanmi Science Co., Ltd

Hanmi Science Co., Ltd

KKRX:008930
41,600.00
KRW
-1,300.00
(-3.03%)
2,226.23EPS
13.53P/E
2.04TMarket Cap
Hanmi Science Co., Ltd
KRX:008930
(Korea Stock Exchange)

Recent

price

41,600.00

P/E

ratio

13.53

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
KRW
12,083.05
254.78
274.18
3,077.04
7,685.71
11,431.24
9,737.71
9,765.64
10,308.72
11,664.81
12,251.37
13,579.72
15,265.44
18,362.8
18,963.69
20,038.55
20,537.06
Revenue per Share
112.59
-222.62
174.16
134.05
307.54
2,629.06
116.18
450.15
262.37
439.12
322.95
613.73
1,010
1,694
878
1,748
2,227.76
Basic EPS, GAAP
-119.77
-127.39
-5.43
-20.99
48.95
598.24
1,031.83
-566.14
22.18
157.97
169.57
164
16.19
389.66
1,054.22
394.95
386.6
Free Cash Flow per Basic Share
100.43
- -
- -
- -
- -
- -
404.27
- -
177.55
177.64
181.23
184.86
192.5
196.19
300.3
199.99
- -
Dividend per Share
5,853.83
5,695.64
6,072.32
6,307.47
6,434.14
8,768.84
9,395.94
9,881.15
9,703.45
9,594.72
9,790.1
10,261.19
10,871.82
11,621.38
12,418.89
14,204.7
15,669.34
Book Value per Share
2,387.7
5,679.15
6,030.24
6,249.39
6,354.1
8,660.84
9,272.57
9,694.75
9,537.33
9,440.01
9,659.1
10,148.47
10,584.91
10,630.61
11,613.44
13,972.17
15,429.33
Tangible Book Value per Share
53
66
72
71
69
68
68
67
69
70
70
70
69
68
68
68
68
Basic Weighted Avg Shares
641,471
16,812
19,646
219,863
532,605
776,215
665,285
652,324
707,995
816,619
857,383
950,165
1,046,054
1,247,906
1,283,432
1,356,958
1,391,246
Sales/Revenue/Turnover
0.64
19.67
18.4
2.86
1.69
18.89
2.26
2.14
1.55
1.98
2.93
3.03
2.69
4.57
2.96
4.2
3.61
Operating Margin (%)
33,822
857
902
1,079
1,367
2,032
3,205
4,684
4,606
6,375
6,208
5,257
5,478
8,732
9,711
9,481
9,331
Depreciation Expense
5,977
-14,691
12,479
9,578
21,312
178,521
7,938
30,069
18,020
30,742
22,601
42,942
69,210
115,122
59,422
118,370
150,915
Net Income, GAAP
- -
473.19
2.9
8.15
- -
24.08
58.02
7.72
4.24
13.23
24.59
12.59
5.66
11.81
10.15
11.5
14.64
Effective Tax Rate (%)
0.93
-87.38
63.52
4.36
4
23
1.19
4.61
2.55
3.76
2.64
4.52
6.62
9.23
4.63
8.72
10.85
Profit Margin (%)
145,558
-10,285
3,942
-9,778
-45,219
93,283
25,279
16,668
17,235
-11,109
-4,386
1,564
-102,378
-121,302
-140,863
-57,775
-40,132
Working Capital
147,527
- -
- -
- -
- -
- -
- -
- -
- -
298
5,275
201
6,483
10,769
1,009
579
496
LT Debt
604,830
372,254
393,893
409,066
417,712
584,250
647,564
665,152
653,094
645,687
658,734
690,295
724,748
787,472
838,704
959,193
1,061,036
Total Equity
- -
-2.55
3.23
2.45
- -
28.33
1.76
5.19
3.66
4.82
3.48
7.01
7.58
11.32
8.58
10.9
12.36
Return on Invested Capital (%)
- -
-2.76
3.48
2.58
- -
32.66
1.31
4.47
2.8
4.73
3.41
6.11
8.71
12.87
7.03
11.52
13.67
Return on Capital (%)
1.49
-3.87
3.26
2.39
5.17
35.71
1.29
4.59
2.73
4.73
3.47
6.37
9.78
15.23
7.3
13.13
15.6
Return on Common Equity (%)

Capital Structure

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
213,952
187,587
183,456
LT Borrowings
- -
- -
- -
LT Finance Leases
579
616
496
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
68
68
68
Market Capitalization
2,454,622
2,512,178
2,041,568

Working Capital

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
425,770
392,065
376,946
Cash, Cash Equivalents & STI
128,173
116,026
98,924
Accounts Receivable, Net
104,389
107,263
116,082
Inventories
122,542
119,548
127,508
Total Current Liabilities
483,545
448,423
417,077
Payables & Accruals
- -
- -
- -
ST Debt
213,952
187,587
183,456
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
5.19%
7.86%
14.37%
Free Cash Flow
274.96%
460.09%
-62.51%
Net Income, GAAP
45.56%
53.67%
99.2%
Sales/Revenue/Turnover
6.14%
9.76%
5.73%
Total Cash Common Dividend
- -
4.82%
-33.37%

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
346,408
309,096
338,039
331,710
1,283,432
2025
352,044
338,269
362,098
285,670
1,356,958
2026
375,621
367,856
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
469
308
263
-161.99
878
2025
370
425
476.74
476.41
1,748
2026
630.46
644
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
100.13
- -
300.3
2025
- -
- -
- -
- -
199.99
2026
- -
- -
- -
- -
- -
Similar Companies
DataMeds AI, Inc. (NASDAQ:MEDS)
Selcuk Ecza Deposu Ticaret ve Sanayi A.S. (BIST:SELEC)
McKesson Corporation (NYSE:MCK)
Ibnsina Pharma (EGX:ISPH)
Cardinal Health, Inc. (NYSE:CAH)
Entero Healthcare Solutions Limited (NSE:ENTERO)
Business
Hanmi Science Co., Ltd. (008930.KS) manufactures and sells pharmaceutical products through its subsidiaries in Korea and internationally; it develops drugs focused on diabetes and anti-cancer treatments, children's and adults' bowel preparation and cold medicines, and cephalosporin antibiotics, while also offering general foods, health functional foods, soy milk, medical equipment, and automated drug management systems sold via online and offline pharmacies. Founded in 1973 and headquartered at 14 Wiryeseong-daero, Songpa-gu, Seoul, South Korea, the company operates primarily in the healthcare sector with 444 employees and targets medical, consumer, and institutional customers across domestic and global markets. In recent developments, Hanmi Science, as part of the Hanmi Pharmaceutical Group, engages in strategic collaborations such as the October 2024 partnership and investment with MEDiC Life Sciences for cancer biomarker discovery to enhance oncology programs, alongside expansions into the Middle East and Latin America through alliances like the September 2025 agreement with Tabuk Pharmaceuticals, and ongoing financial arrangements including the amended September 2025 loan extension with Aptose Biosciences.